Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

NCT03047928 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT03047928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03047928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Lead sponsor
Inge Marie Svane
Phase
Phase 1/2
Overall status
Completed
Start date
February 22, 2018
Completion date
December 31, 2022
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma